We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 33.00 | 32.40 | 32.90 | 33.50 | 32.60 | 32.60 | 215,655 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 52.61M | 2.35M | 0.0052 | 64.42 | 152.4M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/1/2013 16:55 | last year Thursday 19/01/2012 07:00 UKREG Pre-Close Trading Update - this Friday/Monday ? need some news (good) | leoboy | |
10/1/2013 15:26 | We will probably get a pre-close trading update within the next two weeks. | wan | |
10/1/2013 11:21 | The rating is already sky high in anticipation of future performance, on that basis the difference is probably irrelevant in the grand scheme of things! | lomax99 | |
10/1/2013 10:16 | Fair point. | alchemy | |
10/1/2013 09:59 | Reason for preceding spike? I had been looking to add more around 28p, just added a few more at 28.3. | lomax99 | |
09/1/2013 15:49 | Oh offered lower that is good. So Purchase ? but reason for the dip? | alchemy | |
08/1/2013 07:24 | HbA1c White paper - Diabetes Management in a Point of Care Setting By Professor Chris Price, Visiting Professor in Clinical Biochemistry, Department of Primary Care Health Sciences, University of Oxford and Dr Gary Dowthwaite, Product Manager, EKF Diagnostics Summary There are strong arguments for the use of POCT for HbA1c where the performance characteristics of the systems are equivalent to those employed in the central laboratory. POCT offers improved access to testing, as well as enabling immediate clinical decision making, discussion with the patient and implementation of appropriate treatment and/or lifestyle advice. Furthermore POCT enables testing to be undertaken closer to the patient, affords greater convenience for the patient, thereby improving the likelihood of treatment compliance. EKF Diagnostics provides point of care HbA1c analysers certified to international standards (IFCC and NGSP) for point of care testing during screening and monitoring of diabetes | wan | |
07/1/2013 09:58 | Regarding EKF receiving a certificate of Invention Patent from the PRC in relation to patent rights for cuvettes used with Hemo Control; according to EKF new Chinese distributor, 9.6m hemoglobin tests were performed in 2008 across 400 blood banks | azalea | |
07/1/2013 09:41 | Yes, no and yes and yes. The last point is interesting, because EKF's distribution channels have expanded and strengthed significantly. Perhaps also evidenced by EKF apparently 'choosing' not to sell Quo-Lab through an exclusive license. This will be a particularly interesting aspect to watch, given that EKF reported back in September that they had experienced "unexpectedly high initial demand" for Quo-Lab. | wan | |
07/1/2013 08:32 | Is any of their kit proprietary/patented | lomax99 | |
07/1/2013 07:31 | I am not a twitter user, but I noted the following from the Argutus website Latest tweet from Argutus Happy new year to all of our followers. In 2013 there will be some significant changes at Argutus, stay tuned! As I said earlier, I am looking forward to 2013. | wan | |
05/1/2013 12:39 | This morning on BBC TV, Jeremy Hunt in an interview covering fat and sugar levels in food products, said circa 30% of 11 year olds in the UK are either overweight, or obese. Clearly, the problem of obesity and the directly linked potential for severe medical consequences is now being recognised at government level as a major health and financial threat to the country and the NHS. With NICE having approved EKF products for use, it is difficult to imagine this UK company not reaping significant financial rewards in the near term and beyond. | azalea | |
03/1/2013 09:46 | Based on the figures in the Interims, I anticipate the update to the confirm the forecasts made therein to be achieved. The chairman and CEO are two smart foreward looking businessmen who identified a market which is now consuming an ever increasing proportion of health care budgets around the world. | azalea | |
02/1/2013 18:10 | Exactly. Just how does this company stand in this sector's world rankings ? All these supposedly wonderful developments and research here will be worth didly squat,if the majors' huge resources swallow up the whole market as is the norm. All right, maybe that's too simplistic,and there's more to it than that, but without an in depth knowledge of the marketing side of things, rather than being bamboozled with huge amounts of medical blurb,an uninformed investor might as well buy a lottery ticket. | corrientes | |
02/1/2013 15:05 | The world outlook for diabetes does indeed look bad, but unless this co. gets some sales going, it won't make a lot of difference, even if we all had it; (god forbid). | cestnous | |
02/1/2013 14:31 | Most importantly, the Fiscal Cliff agreement will protect Obama's Medicare Bill from the cuts that will have to be made elsewhere in the coming months. Over the past few months alarm bells on obesity and diabeties have been sounding in the media, NHS and parliament. If one were to be paranoid about health warnings I could be persuaded into thinking that talk suggesting mildly obesity is not a problem is tantamount to wanting to kill off afflicted people rather than cure them. Whatever the cause, extra weight leads to lower activity, greater strain on the heart and joints, never mind diabetes. A heathly eating lifesyle not only wards off the common diseases, but also in many cases increases longevity and quality of life; a great combined goal to aim for. | azalea | |
02/1/2013 09:14 | The Guardian reports that the UK is fifth in the world for the number of children with Type 1 diabetes. | azalea | |
02/1/2013 07:32 | So the BBC saying diabetes will account for 10% of the total NHS budget as obesity becomes more widespread half of all adults obese by 2050? Looks good, going forward, for ekf. | andrbea | |
28/12/2012 07:50 | Azalea...Duly noted. It was perhaps more interesting to note that he does not have any immediate plans to sell the shares (not even to pay any tax), which suggests he is seeing greater value/opportunity beyond that provided today. I am also looking forward to 2013. | wan | |
27/12/2012 10:45 | I note non exec director Hall exercised options and bought 500k @ 20p on the 18/12. | azalea | |
24/12/2012 09:32 | To all readers and contributors, I wish you a happy and relaxing festive break and a very happy and healthy New Year. | wan | |
20/12/2012 17:57 | Looking for a pre closing statement- third week in January. | azalea | |
14/12/2012 09:55 | There is hardly a week that goes by when there is not a mention in the news on diabetes and related diseases.Health Secretary Jeremy Hunt will have his work cut out living up to his statement of the NHS providing "excellent care"; when we know from the recent House of Lords debate that there are very few hospitals with equipment and trained personnel able to meet the 'expectations'. | azalea | |
14/12/2012 08:24 | December 13, 2012 5:07 pm December 13, 2012 Infections drop down list of big killers By Andrew Jack in London In the past two decades, global life expectancy has risen on average by 10 years and age-adjusted mortality and disability have fallen for most diseases, although exceptions include diabetes, Alzheimer's and chronic kidney disease, according to the study, which covers the period 1990-2010. Full story - The Lancet Global Burden of Disease Study 2010 Published Dec 13, 2012 | wan | |
12/12/2012 07:37 | Diabetes fuelled TB seen rising in Hyderabad TNN Dec 11, 2012 HYDERABAD: Having already earned the ignominy of being called the diabetic capital of India, Hyderabad is now staring at rising tuberculosis (TB) cases fuelled by diabetes. | wan |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions